November 16, 2011
AURORA, Ontario, November 16, 2011 – Helix BioPharma Corp. (TSX, NYSE Amex, FSE: “HBP” or “the Company”)
announces that its Board of Directors (the “Board”) appointed a special committee of independent directors (the “Special
Committee”) to advise the Board with respect to the Company’s annual general meeting of shareholders to be held on January 30, 2012 (the “Meeting”). The members of the Special Committee are Jack M. Kay and W. Thomas Hodgson. The Special
Committee is being advised by Norton Rose OR LLP.